2
Introduction
CD40 is a cell surface-expressed glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily and plays a central role in the immune system (1) . It is expressed on a variety of immune cells, such as B cells, dendritic cells (DC), monocytes and macrophages, but also on several tumors, such as B cell lymphomas and carcinomas (1) .
CD40 agonists trigger effective anti-tumor responses in pre-clinical models (2;3). These responses occur via two distinct mechanisms: (i) tumor-specific immune responses, and (ii) direct tumoricidal effects such as apoptosis and antibody-dependent cellular cytotoxicity (ADCC) (2) . The indirect anti-tumor immune effect, which is independent of the CD40 status of the tumor, is mediated by tumor-specific cytotoxic T lymphocytes (4) (5) (6) , and possibly macrophages in certain tumor types (7) . The direct tumoricidal effects, on the other hand, depend highly on the CD40 expression of the tumor.
Several clinical trials have been reported for agonistic CD40 antibodies (2;8),
including CP-870,893 (IgG2) (9) , ChiLob 7/4 (10) and SGN-40 (IgG1), the latter being a weak CD40 agonist (11) . Systemic administration of CD40 agonists may result in dose-limiting immune-related adverse effects, such as cytokine release syndrome (12;13) . Recently, it was demonstrated that local administration of agonistic CD40 antibodies into tumor-bearing mice resulted in improved anti-tumor effect, and caused less adverse immune-related events than systemic treatment (4;14;15) . The concept of intra-tumoral CD40 stimulation has also been validated using local injection of adenoviral vectors expressing CD40L, demonstrating antitumor effects in human and murine bladder cancer as well as in dog melanoma, with minimal side effects (16;17) .
To translate these findings into the clinic, we set out to engineer a CD40 agonistic antibody (18;19) , ADC-1013, using Fragment INduced Diversity (FIND®) (20) . The affinity and potency of the antibody was increased since these properties are likely to be of importance for local administration but also advantageous for systemic administration.
Initially, the anti-tumor effect of the optimized antibody was evaluated on a EJ human bladder 
Material and methods

Antibodies and cell lines
ADC-1013 was optimized as described in Supplementary methods (see also Supplementary Table 1 ), S2C6 (23) (chimeric, human γ1/κ) and B44 (19) were produced by transient expression in HEK cells and subsequent purification on protein A columns. An aglycosylated variant of ADC-1013, referred to as ADC-1013-N297Q, was produced by introducing a single N297Q mutation in the Fc-region. Endotoxin levels were analyzed using the Quantitative LAL test using Endosafe -Portable Test System (PTS). Agonistic rat-anti-mouse CD40 (clone: FGK4.5) and rat IgG2a (clone: 2A3) were purchased from Bio X Cell (West Lebanon, NH, USA). The hCD40 positive Raji cell line was cultured in R10 medium (RPMI-1640 supplemented with L-glutamine and 10% FBS), at 37°C and 5% CO 2 . The human EJ bladder cancer cell line (21) was cultured in R10 medium supplemented with 100 U/ml PenicillinStreptomycin (PEST) at 37°C and 5% CO 2 . EJ cells were confirmed CD40 positive and HLA-A2 negative. The murine bladder transitional cell carcinoma cancer cell line Mouse Bladder-49 (MB49; a kind gift from Dr. K. Esuvaranathan, National University of Singapore, Singapore in 1996) and Lewis lung carcinoma-1 (LLC-1) (ATCC, CRL-1642) were cultured in DMEM+ GlutaMax supplemented with 10% FBS, 0.1mM sodium pyruvate, 100U/ml Penicillin-Streptomycin at 37°C and 5% CO 2 . Human CD40 positive MB49 was transfected with human CD40 expressing vector under the control of CMV promotor. For cross-linking of cells and CD56 + NK cells were isolated using magnetic bead separation (MACS) according to the manufacturer's protocol (Miltenyi Biotec, Bergish Gladbach, Germany). Monocytes were cultured for 6-7 days in R10 with recombinant human IL-4 and GM-CSF with medium changed every second day and moDCs were confirmed to be CD1a high and CD14 -by flow cytometry. T cells for the in vivo experiments were isolated using Dynabeads Untouched
Human T cells-kit according to the manufacturer's protocol (Invitrogen Life Technologies, Carlsbad, CA, USA).
Flow cytometry
The flow cytometry used to analyze the human cells in vitro has been described previously (24) . 
In vitro cell assays in human cells
Research. The human CD40 transgene mice contains the hCD40 sequence downstream of the murine CD40 promotor and regulatory elements (26) and do not express murine CD40 (27) (Supplementary Methods). The mice were analyzed for human CD40 expression by immunohistochemistry using tissue cryo sections from spleen, lymph node, pancreas, CNS, liver, lung and kidney from one female and one male hCD40tg mouse. Human and mouse spleen was used as positive and negative controls. Briefly, the sections were blocked in 5% normal mouse serum (Jackson ImmunoResearch Laboratories) and stained with mouse anti- 
In vitro immune activation profiling in cells from hCD40tg mice
Research. BMDCs were additionally stimulated with or without LPS (1µg/ml) in vitro and pulsed with hgp100 (1µg/ml) before injected i.v into naïve wt C57BL/6 mice (1x10 6 cells/mouse), which were injected i.v the day before with CFSE labeled splenocytes (11 x10 6 cells/mouse) isolated from pmel mice. The in vivo proliferation of pmel CD8+ cells was analyzed using flow cytometry four days post BMDC injection.
In vivo experiments in syngeneic MB49 bladder cancer model
Research. caliper. Blood was taken 4 hours after every injection and serum or plasma was obtained.
Free antibody levels in serum were measured by a sandwich ELISA specific for human γ1
and λ chains or specific for human CD40.
Immunological memory
To characterize the immunological memory, T cells were depleted in naïve and tumor- 
Ethical considerations and statistical analyses
Animals were housed according to regional regulations. All animal experiments were approved by the regional Ethics Committees in Lund/Malmö and Uppsala, Sweden.
Statistical analyses were performed using GraphPad prism software (GraphPad Software, Inc, La Jolla, CA).
Results
Selection of ADC-1013, a CD40 agonist optimized for local immunotherapy of cancer
B44 (18), a CD40 agonist with moderate affinity (Supplementary Table 2 ) was used as template for four focused libraries designed to generate functional diversity for FIND recombination and lead optimization ( Figure 1 ) (20) . The starting phage libraries were subjected to a first round of selection and the outputs were subsequently recombined using FIND, creating a new library combining functional diversity from all the sublibraries. The FIND-recombined library was subjected to four additional rounds of selection with increasing stringency and the output from each selection was expressed in scFv format, and 2000
clones from each selection round were analyzed in a concentration independent HTS assay.
The 95 unique clones with the highest affinity were re-expressed in IgG format, and the selected clones were further analyzed in Biacore demonstrating affinities for most of the variants in the order of 10-40 pM ( Figure 1 ). The agonistic properties of the selected variants were confirmed using a B cell proliferation assay (data not shown). As the tumor milieu is acidic in many tumors (28) the kinetic constants were measured at a low pH (5.4) at 37°C. This allowed selection of a lead candidate (ADC-1013) with 100-fold increased affinity (KD 1 × 10 -11 M, at pH 7.4, 37°C) compared to B44 at both physiological and acidic pH (Supplementary Table 2 ). The EC50 value for binding to CD40 expressing cells was increased approximately 30 fold (Supplementary Table 3 ). Analysis of the structure model indicates that one of the three mutated positions directly changes the surface charge of the paratope, whereas the other two mutations may induce conformational changes ( Figure 1D ).
Moreover, ADC-1013 had 3 to 5-fold increased potency compared to B44, as measured by B cell proliferation assay or activation of moDCs (Supplementary react with murine, rat or canine CD40, but has similar affinity to cynomolgus monkey CD40 and hCD40, evaluated by binding to peripheral B cells by flow cytometry and B cell proliferation assay (data not shown).
In vitro characterization of ADC-1013
The primary mode of action of ADC-1013 is the activation of immune cells and specifically The binding to FcγR affects the agonistic properties of CD40-directed antibodies as recently described by several groups (31) (32) (33) . The FcγR dependency of ADC-1013 was assessed using ADC-1013N297Q, in the DC assay. CD86 was significantly less up-regulated by ADC-1013N297Q (CD86 MFI not above background, Figure 2D ) than by ADC-1013. The ability to up-regulate CD86 was restored upon cross-linking with an antihuman IgG (Background subtracted MFI 130, Figure 2D ).
Inhibition of growth of human bladder cancer in NSG mice repopulated with human DC and T cells.
In order to evaluate ADC-1013 in vivo, we initially used a xenograft model. Immunodeficient wild-type and the hCD40tg strain. As expected, the bulk T cell pool from both hCD40tg mice and wild-type mice expressed very low levels of mCD40 and hCD40 respectively (Supplementary Table 4 Figure 4A ) in an hCD40-specific manner. Induction of IL-12 in BMDCs from wt mice following stimulation with a mouse CD40 specific antibody, FGK4.5, exhibited a similar pattern ( Figure 4B ). Furthermore, CD11c + cells purified from hCD40tg mouse spleen could be stimulated by ADC-1013 in a target-dependent manner ( Figure 4C ).
In an in vitro T cell priming experiment, BMDCs loaded with hgp100 together with ADC-1013
or an isotype control antibody were co-incubated with CFSE-labeled hpg100-specific pmel T cells. The resulting T cell activation was dependent on ADC-1013 induced CD40 activation ( Figure 4D ). We also assessed if BMDCs from hCD40tg and CD40 -/-mice responded equally well to a CD40-unrelated stimuli by in vitro loading and maturation of BMDCs with hgp100
together with LPS and transfer into mice that had received naive pmel T cells the day before.
The pmel cells proliferated equally well in vivo when using BMDCs from either strain ( Figure   4E ). Peptide-loaded hCD40 BMDCs (control) induced a very low, but significantly increased, pmel T cell proliferation in spleen compared to peptide loaded CD40 -/-BMDCs ( Figure 4E ).
ADC-1013 eradicates CD40 negative bladder tumors and generates T cell-dependent tumor immunity
The hCD40tg mice enabled the evaluation of in vivo anti-tumor effects of ADC-1013 in an immunocompetent host using a second, syngenic tumor model. Figure 5D ) indicating that the tumor immunity is T cell dependent. Isotype control-treated hCD40tg mice also exhibited more tumor growth arrest than CD40 -/-animals ( Figure 5B ), which appears to depend on an endogenous T cell response unrelated to the isotype antibody ( Figure 5D , non-treated naïve animals with and without T cells). In addition, the anti-tumor memory was specific, as complete responders rechallenged with an irrelevant LLC-1 tumor succumbed to tumor growth ( Figure 5E ).
Research. 
Target-dependent decrease of free ADC-1013 in serum 4h after local administration
Serum collected from ADC-1013 or isotype-treated hCD40tg mice demonstrate that the antibody levels in serum 4h after injection of ADC-1013 were more than 100-fold lower than those of the isotype control antibody ( Figure 6A ). To confirm that the effect was target dependent, ADC-1013 was measured in CD40 -/-mice, where serum levels were similar to the isotype control antibody ( Figure 6B ).
Increasing the affinity to CD40 should also enable the antibody to be released more slowly from the injection site, thereby decreasing the Cmax and minimize systemic side effects. To demonstrate this, the serum levels 4h after local injection of B44 and ADC-1013 into hCD40
positive Raji tumors on SCID mice was measured indicating that the higher affinity of ADC-1013 resulted in slower systemic release of the antibody ( Figure 6C ). A similar trend was seen in hCD40tg mice where the serum levels were measured 4h post treatment at days 7 and 10. The serum levels of ADC-1013 were low compared to levels of B44 (0.011 ug/ml for ADC-1013 compared to 0.078 ug/ml for B44 at day 10, Figure 6D ). The antitumor effect of B44 is similar to ADC-1013 ( Figure 6E ). To further demonstrate that the increased affinity of Table 2) , and a very fast on-rate (k ass ). The on-rate may be of particular importance for local administration. When an antibody is administered locally, it will immediately start to leak out of the tumor area, and the on-rate for the binding reaction will be a limiting factor (40) . Further, the increased affinity and potency of ADC-1013 would also be advantageous when administered systemically. The comparison of ADC-1013 and the starting clone (B44) shows that the affinity maturation delayed the release from the injection site. We showed this using two mouse models, the xenograft model with hCD40
-SCID mice and an hCD40 + Raji tumor, and in hCD40tg mice using hCD40+ syngeneic tumors. The resulting slower release from the injection is important for local immunotherapy, but may also be of clinical interest when administering the antibody systemically, e.g. subcutaneously.
However, further studies on the distribution in tumor, tissue and blood using radiolabeled antibody, may be warranted to confirm these findings.
Several groups have demonstrated that agonistic effects of anti-CD40
antibodies depend on FcγR binding (31;32) . Herein, we demonstrate that the agonistic effect 
Reports exist on hCD40-expressing transgenic mice, in which hCD40 expression has either been restricted to B cells (43), or included DCs under the control of the murine I-E-alpha promotor (44). However, functional analysis of CD40-targeted therapy has not been published. The hCD40tg mice were mapped for CD40 expression in the immune cell compartment (Figure 3 and Supplementary Table 4) revealing that hCD40 expression on hCD40tg mice was comparable to mCD40 expression on wt mice on endogenous DCs (CD8 + and CD8 -). Expression was confirmed on macrophages and, at a lower level, the B cells. 
Our pharmacokinetic measurements demonstrate that the distribution of ADC-1013 is highly target-dependent, which is in line with previous work on murine CD40 agonistic antibodies (4). This strong target-mediated effect on the serum levels of ADC-1013 is likely a result of the target distribution, redistribution and antibody internalization following administration (4;45). Anti-drug antibodies (ADA) are not likely to affect the measurements, since the samples were taken within 3 days after the first treatment (4). These finding correlates well with clinical studies carried out with CD40 agonistic antibodies (9;12), and lends further support to the translational relevance of the hCD40tg mice.
We used an MB49 bladder cancer model to further investigate ADC-1013 therapy in hCD40tg mice. Importantly, this syngeneic tumor lack hCD40, ensuring that only the immunological anti-tumor effect was assessed. Our data demonstrate that local ADC-1013 therapy effectively cures bladder cancer tumors in a dose and host CD40-dependent manner. The mice that were cured by ADC-1013 treatment were immune to re-challenge more than 5 month after cure. This immunity was eliminated following depletion of CD4 and We and others has previously demonstrated that that local CD40 treatment generates a systemic immune response (14; 15) . These studies were corroborated in this study showing effect also on distal, untreated tumors. The systemic Cmax in mice treated peritumorally with 100 µg ADC-1013 is approximately 30 ng/ml (data not shown), which is three times lower than the EC50 for cell activation ( Figure 2, 4 Table 4 for specific markers that were used to gate out the individual populations. Murine and human CD40 expression patterns displayed as red contour plots were compared using the CD40-/-strain as the negative background (i.e. the CD40-/-splenocytes were stained with the anti-mouse or anti-human CD40 antibody to visualize true CD40 expression) displayed as blue contour plots. Murine CD40 expression (wt) is shown in the upper row and human CD40 expression (hCD40tg) in the lower row.
Wildtype and hCD40tg mice shown as a red population and CD40-/-mice are illustrated in blue for both rows. 3 mice per group were analyzed and a representative figure is shown. 
